Nina Steele
Assistant Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (23)
Identifying spatially variable genes (SVGs) has been an essential task in spatial transcriptomics. In addition to SVGs detection, there are genes exhibiting expression patterns that are associated with cellular developmental stages or lineage fates across a tissue section. Identifying such genes could provide novel insights into tumor metastasis. Here, we introduce a unified statistical model, termed TrajEctory-preServed and SpAtially-variable gene detection (TESSA), to detect both types of genes. Moreover, we propose a novel strategy to address the inherent double-dipping issue commonly encountered when assessing temporal gene effects in transcriptomics analysis. We demonstrate the testing performance through extensive simulation studies and real applications to several publicly available datasets. Downstream analyses further highlight the potential of our method in identifying genes associated with tumor progression and enhancing spatial domain detection.
Year:
2025
Supplementary Figure S4. CK5 and CK17 do not predict treatment response or time to recurrence. A) Combining CK5 and GATA6 IHC does not predict overall survival. B) CK17 high, GATA6 low tumors display improved survival compared to CK17 low, GATA6 high tumors. C) Kaplan-Meier survival curves for CK5 positive and negative tumors treated with first-line gemcitabine chemotherapy. D) Kaplan-Meier survival curves for CK17 positive and negative tumors treated with first-line gemcitabine chemotherapy. E) CK5 status does not predict time to recurrence. F) CK17 positive tumors show longer time to recurrence than CK17 negative tumors, the opposite phenotype expected from the basal subtype.
Year:
2025
Supplementary Figure S6. GATA6 expression predicts chemotherapy response to GnP but not mFFX. A) GATA6low metastatic tumors have significantly worse overall survival when treated with combination GnP first-line chemotherapy. B) GATA6 status does not predict overall survival when patients receive first line mFFX chemotherapy.
Year:
2025
Supplementary Figure S3. Consort Diagram and Mixed Populations. A) Consort diagram of analyzed samples. For survival analyses, all patients with intact cores (n = 491) were assessed. For treatment response analyses, patients were further subdivided by type of chemotherapy received, and neoadjuvant-treated samples were considered separately (n = 51). B) Mixed (HMGA2+ GATA6+) and double negative (HMGA2- GATA6-) populations show intermediate survival between basal and classical tumors.
Year:
2025
Supplementary Figure S2. Demographic data for analyzed cohort. A) Age distribution for TMA and Ochsner cohorts. B) Race distribution for TMA and Ochsner cohorts. C) Proportions of disease by stage (left) and resulting survival (right) predicts survival in TMA cohort (AJCC 8th edition).
Year:
2025
Supplementary Figure S6. GATA6 expression predicts chemotherapy response to GnP but not mFFX. A) GATA6low metastatic tumors have significantly worse overall survival when treated with combination GnP first-line chemotherapy. B) GATA6 status does not predict overall survival when patients receive first line mFFX chemotherapy.
Year:
2025
Supplementary Figure S3. Consort Diagram and Mixed Populations. A) Consort diagram of analyzed samples. For survival analyses, all patients with intact cores (n = 491) were assessed. For treatment response analyses, patients were further subdivided by type of chemotherapy received, and neoadjuvant-treated samples were considered separately (n = 51). B) Mixed (HMGA2+ GATA6+) and double negative (HMGA2- GATA6-) populations show intermediate survival between basal and classical tumors.
Year:
2025
Supplementary Figure S4. CK5 and CK17 do not predict treatment response or time to recurrence. A) Combining CK5 and GATA6 IHC does not predict overall survival. B) CK17 high, GATA6 low tumors display improved survival compared to CK17 low, GATA6 high tumors. C) Kaplan-Meier survival curves for CK5 positive and negative tumors treated with first-line gemcitabine chemotherapy. D) Kaplan-Meier survival curves for CK17 positive and negative tumors treated with first-line gemcitabine chemotherapy. E) CK5 status does not predict time to recurrence. F) CK17 positive tumors show longer time to recurrence than CK17 negative tumors, the opposite phenotype expected from the basal subtype.
Year:
2025
Supplementary Figure S2. Demographic data for analyzed cohort. A) Age distribution for TMA and Ochsner cohorts. B) Race distribution for TMA and Ochsner cohorts. C) Proportions of disease by stage (left) and resulting survival (right) predicts survival in TMA cohort (AJCC 8th edition).
Year:
2025
Purpose: The purpose of this study was to establish HMGA2 as a marker of basal-like disease in pancreatic ductal adenocarcinoma (PDAC) and explore its use as a biomarker for prognosis and treatment resistance. Experimental Design: We identified high-mobility group A2 (HMGA2) protein expression in basal PDAC cells in a single-cell RNA sequencing (RNA-seq) atlas of 172 patient samples. We then analyzed HMGA2 expression, along with expression of the classic marker GATA-binding factor 6 (GATA6), in a cohort of 580 PDAC samples with multiplex IHC. We further supplemented these data with an additional 30 diverse patient samples and multiple independent single-cell RNA-seq databases. Results: We found that expression of HMGA2, but not previously described basal markers cytokeratins 5 or 17, predicted overall survival in our cohort. Combining HMGA2 and GATA6 statuses allowed for the identification of two key study groups: an HMGA2+/GATA6− cohort with worse survival, low tumor-infiltrating CD8 + T cells, increased FAP+ fibroblasts, and poorer response to gemcitabine-based chemotherapies ( n = 94, median survival = 11.2 months after surgery) and an HMGA2−/GATA6+ cohort with improved survival, increased CD8 + T-cell infiltrate, decreased FAP+ fibroblasts, and improved survival with gemcitabine-based chemotherapy ( n = 198, median survival = 21.7 months after surgery). HMGA2 was also prognostic for overall survival in RNA-seq from an independent cohort. Conclusions: IHC stratification of primary tumors by HMGA2 and GATA6 statuses in pancreatic cancer is associated with differential outcomes, survival following chemotherapy, and tumor microenvironments. As a nuclear marker for basal disease, HMGA2 complements GATA6 to identify disease subtypes in PDAC.
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Collaborators (34)
Janusz Franco-Barraza
Assistant Research Professor
Fox Chase Cancer Center
Jonathan Preall
Research Associate Professor
Cold Spring Harbor Laboratory
Michael Feigin
Assistant Professor
Roswell Park Comprehensive Cancer Center
Yuehua Cui
Michigan State University
Rachael Safyan
Assistant Professor
University of Washington
Rosalie C. Sears
Professor; Co-Director Brenden Colson Center for Pancreatic Care
Oregon Health & Science University
Howard Crawford
Professor
University of Michigan
Allison R. Schulman
University of Michigan
Pierre A. Coulombe
G. Carl Huber Professor and Chair
University of Michigan
Jorge Machicado
Assistant Professor
University of Michigan
Marina Pasca Di Magliano
Associate Professor
University of Michigan
yuesong wu
Michigan State University
Yuying Xie
Associate Professor
Michigan State University
Sita Kugel
Professor
Fred Hutch Cancer Center
David G. DeNardo
Professor of Medicine
Washington University School of Medicine
Ling Huang
Assistant Professor
Michigan State University
Vaibhav Sahai
University of Michigan
Sunil Hingorani
Fred Hutchinson Cancer Research Center
E. Gabriela Chiorean
Professor of Medicine
University of Washington
Jiaqi Shi
Professor
University of Michigan
Abdulrahman Alahmari
Assistant professor
prince sattam bin abdulaziz university
Filip Bednar
University of Michigan
Kiran Vij
Associate Professor
Washington University in St. Louis
Craig Galban
Professor
University of Michigan
Ryan C. Fields
University of Rochester
Kathleen DelGiorno
Assistant Professor
Vanderbilt University
Timothy Frankel
Assistant Professor
University of Michigan Hospital
Mukund Seshadri
Roswell Park Comprehensive Cancer Center
Yaqing Zhang
Associate Professor
University of Michigan
Rosa Menjivar
University of California, San Francisco
Christos Fountzilas
Associate Professor
Roswell Park Comprehensive Cancer Center
William Burns
Assistant Professor
Johns Hopkins University School of Medicine
Mark D. Parker
Associate Professor
University at Buffalo
Stefanie Galban
-
Make your next move.
Prepare your application
Review drafts before you send them.